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Sdescending branch (odds ratio 17,70; 95 percent conﬁdence interval 4,89 to 64,55; p
<0.001) after primary PCI.
Conclusions: Restoration of TIMI ﬂow  2 in all major RV branches during primary
percutaneous coronary intervention, as well as the absence of distal embolization of
the posterior descendent artery, results in lack of cardiovascular magnetic resonance
late enhancement in the right ventricular wall after procedure, regardless of initial
angiographic status.Parameter OR 95% CI p
3-vessel disease 0,433 0,193-0,974 0,043
EF < 50% 0,377 0,160-0,888 0,026
Age > 75 years 0,29 0,114-0,740 0,01
Renal failure 0,259 0,100-0,675 0,006
LM culprit vessel 0,062 0,006-0,601 0,016TCT-225
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Background: The SYNTAX score (SS) has demonstrated strong prognostic utility for
ischemic outcomes in patients undergoing PCI for stable ischemic disease, non-ST-
segment elevation acute coronary syndromes (NSTEACS), and STEMI. We sought to
determine the relationship between the SS and bleeding risk in patients undergoing
percutaneous coronary intervention (PCI) for NSTEACS.
Methods: We stratiﬁed 2,627 patients from the ACUITY in whom PCI was per-
formed into SS groups based on score tertiles (SS <7, 7-12, and >12). Thirty-day
major bleeding rates were determined for each group.
Results: As demonstrated in the Figure, 30-day major bleeding rates were signiﬁ-
cantly greater in the highest SS tertile (>12) compared with intermediate (7-12) and
lowest (<7) tertiles. By multivariable analysis, the SS was independently associated
with 30-day major bleeding (HR per 1 SS point: 1.03, 95% CI: 1.01 to 1.04;
p¼0.003).
Conclusions: In the large-scale ACUITY trial, in addition to its previously described
prognostic utility for adverse ischemic events, the SS was independently associated
with major bleeding after PCI for NSTEACS.TCT-226
Impact of baseline renal failure on long-term clinical outcomes after primary
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Background: Renal failure (RF) is associated with increased cardiovascular mortality
in patients with acute coronary syndromes (ACS). Nevertheless patients with RF are
less likely to receive reperfusion therapy during AMI. This study is the ﬁrst reportB74 JACC Vol 62/18/Suppl B j October 2from a contemporary randomized controlled trial (RCT) addressing the impact of RF
on long-term clinical outcomes in patients undergoing primary PCI for AMI.
Methods: 745 patients with STEMI underwent primary PCI were enrolled in this
study and were divided in two groups according with the baseline estimated creatinine
clearance (calculated by the use of the Cockcroft-Gault formula) and the National
Kidney Foundation criteria (group A: 176 patients, class III-IV-V; group B: 569
patients, class I-II).
Results: Multivariate logistic regression shows a signiﬁcantly correlation of RF with
3-years cardiovascular death (Table 1). Kaplan-Meier analysis show a signiﬁcantly
decreased of the event-free survival curves for 3-years CV death (log rank <0,001,
Figure 1) in patients with RF.Conclusions: RF is signiﬁcantly associated with 3-years CV death in patients with
AMI treated with successful primary PCI despite no differences in term of treatment
between patients with or without RF.
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Background: Although PPCI has become the preferring reperfusion modality for
STEMI nowadays, thrombolysis remains useful when PPCI will be remarkably
delayed, which is still common in real practice. However, there’re concerns on the
weakness of single thrombolysis, especially re-occlusion of the vessel. It has been
suggested that early PCI after thrombolysis might improve its efﬁcacy. We used CMR
to further investigate this “pharmacoinvasion” strategy.
Methods: Current data came from an ongoing RCT comparing pharmacoinvasion and
PPCI for STMEI within 12h. Pharmacoinvasion was composed of r-TPA thrombolysis
and angiography/PCI 3-24h thereafter except for thrombolysis failure, in which
situation a rescue PCI would be done immediately. CMR was performed 2-8d after
reperfusion.
Results: 51 in pharmacoinvasion and 49 patients in PPCI group received CMR assay,
representing 80.1% of total patients. Rate of successful thrombolysis was 84.4%
(TIMI ﬂow grades2 in culprit artery). Median time between thrombolysis and
angiography was 7.7h (3.6 to 16.5h). 49 in pharmacoinvasion and all patients in PPCI
group received stenting. Symptom-to-CMR time and other baseline characteristics
were similar except for door-to-reperfusion time (door-to-needle/door-to-balloon time
for thrombolysis/PPCI), which was signiﬁcantly shorter in pharmacoinvasion group
(4422min vs. 8641min, p<0.001). Most of the CMR results were statistically
equal between pharmacoinvasion and PPCI arms: LVEF 52.210.7% vs. 4911.7%,
p¼0.167; Intramyocardial hemorrhage 43.1% vs. 48.9%, p¼0.548; Microvascular
obstruction (MVO) 64.7% vs. 65.3%, p¼1.000; MVO size (proportion to LV
myocardium) 2.02.8% vs. 2.12.9%, p¼0.818. However, infarction size (pro-
portion to LV myocardium) was signiﬁcantly lower in pharmacoinvasion group:
23.512.3% vs. 29.716.2%, p¼0.034.
Conclusions: Current CMR data suggested that pharmacoinvasion strategy may have
comparable efﬁcacy as PPCI. Much shorter door-to-reperfusion time showing in this7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
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Sstudy may be the major reason for smaller infarction size, which might translate to
a better long-term prognosis. Expansion of sample size may help to get more
persuasive conclusion.
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Does intracoronary administration of metabolic cytoportector Mexicor during
rescue PCI limit reperfusion injury of the myocardium in patients with AMI.
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Background: To date, endovascular reperfusion is the essential method for the
treatment of AMI, however it has some negative aspects, such as reperfusion injury of
the myocardium, distal embolism, etc. Intracoronary administration of drugs provides
their fast transport to the target organ and can play a decisive role in the improvement
of the results of treatment of AMI.
Methods: The study comprised 253 patients (average age - 567 years) with acute
occlusion of the proximal or middle segment of the LAD and absent antegrade blood
ﬂow (TIMI 0), who underwent successful recanalization of IRA within the ﬁrst 6
hours after the onset of AMI. Prior to angiography, all patients were randomized into 2
groups. Patients from Group I (n¼126) received intracoronary Mexicor (0,2 g).
Patients from Group II (control, n¼127) did not receive. Intracoronary administration
was performed through a special microcatheter during 10 min. Blood samples for
markers of cardiomyocytes injury (Troponin I, myoglobin) were taken during
recanalization of IRA, in 12 and 24 hours after the procedure.
Results: In-hospital course of the disease was rather uneventful, 1 patient (0,8%) died
in Gr. I and 3 (2,3%) – in Gr. II. Average values of Troponin I at 12 hours after the
procedure in Grs. I and II were 31147 and 63239 ng/ml, respectively (p<0,05). In
the long-term after the procedure, in average – in 6,80,7 months, the survival in Gr. I
was 96,8%, in Gr. II - 87,6% (p>0,05). Baseline clinical indices in both groups were
not signiﬁcantly different. The increase of LV EF in Grs. I and II was 9,25,1% and
4,18,2%, respectively (p<0,05). We also noted a signiﬁcantly better dynamics of
contractility on infarct-related segments of the LV in Gr.I in comparison with Gr. II
(p<0,05) (table 1).
Conclusions: Our study suggests that intracoronary administration of metabolic
cytoprotector Mexicor Upoin accordance with a special technique limits reperfusion
injury of the myocardium and contributes to the preservation of structural and func-
tional integrity of cardiomyocytes after antegrade blood ﬂow restoration in IRA within
the ﬁrst hours after the onset of AMI.
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Background: Rapid time to reperfusion in STEMI is required to maximize
myocardial salvage. Conversely, reperfusion success is diminished in patients pre-
senting late. In the randomized MASTER trial, the MGuard Embolic Protection Stent
was shown to improve TIMI-3 ﬂow and ST-segment resolution (STR) compared to
control DES or BMS. We thus sought to evaluate the impact of symptom onset to
balloon time on the efﬁcacy of this novel device.
Methods: The MGuard is a novel thin-strut metallic embolic protection stent with
a PET micronet covering designed to trap and exclude thrombus and friable athero-
matous debris and prevent distal embolization. A total of 433 patients with STEMI
<12 hours in duration undergoing PCI were randomized to either the MGuard stent
vs. a control (BMS or DES) stent.
Results: Symptom onset to balloon time was <180 minutes in 157 pts, and 180
minutes in 253 pts. Pts reperfused early vs. late were more likely to achieve complete
STR (58.6% versus 47.0%, P¼0.02), and had more rapid cTFC (15.0 vs. 18.0 frames,
p¼0.005). In the entire patient cohort, complete STR and TIMI-3 ﬂow were signiﬁ-
cantly improved with the MGuard stent compared to control stents (57.8% vs. 44.7%,
P¼0.008; and 91.7% vs. 82.9%, p¼0.006, respectively). The results of
stent randomization according to symptom onset to balloon time (SBT) appear in the
table.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Compared to standard stents, the MGuard Embolic Protection Stent
improves reperfusion success in both patients with rapid and delayed time to reper-
fusion, although the absolute magnitude of beneﬁt may be greater in patients with
delays from symptom onset to reperfusion.
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Background: Longer delay from symptom onset to reperfusion has been linked to
increased mortality and worse clinical outcome. The mechanism underpinning this
association is not entirely clear. Thus, we evaluated the impact of the delay from
symptom onset to reperfusion(<3 vs. 3 h) on infarct size and clinical outcomes at 30
days and 1 year in patients with STEMI) treated with primary PCI.
Methods: The INFUSE-AMI trial randomized patients with anterior STEMI under-
going primary PCI with bivalirudin anticoagulation to intralesion (IL) bolus abcix-
imab vs. no abciximab, and to thrombus aspiration vs. no aspiration. The primary
endpoint was cMRI infarct size (IS, % of left ventricular mass) at 30 days. Time to
reperfusion was classiﬁed as <3 vs. 3 h.
Results: There were 280 (62%) patients with <3h delay and 170 (38%) with 3h
delay. Patients with longer delay were signiﬁcantly older, more often women and
diabetics. IS was marginally smaller in patients with shorter delay to reperfusion
(16.4% [6.5, 22.9] vs. 18.1% [10.5, 24.8], respectively, P¼0.07). However, shorter
delay to reperfusion was not associated with higher rates of ﬁnal TIMI 3 ﬂow or
myocardial blush grade 2/3. There was signiﬁcantly lower mortality and morbidity at
30 days and at 1 y in patients with shorter delay (Figure). Delay 3h was an inde-
pendent predictor of 1-year MACCE, but not of death or MACE.
Conclusions: Even with contemporary primary PCI, longer delay to reperfusion
negatively impacts clinical outcome. This effect appears not to be mediated by less
successful reperfusion or by a markedly larger infarct size.TCT-231
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Background: Patients with a history of CABG have traditionally been excluded from
randomized studies comparing PCI and CABG. The optimal revascularization strategy
in these patients is not well deﬁned. We therefore sought to evaluate the relationship
between revascularization strategy and outcomes in patients with prior CABGacts/POSTER/STEMI/NSTEMI/ACS B75
